Search Result

Isoforms Recommended:	NMDA Receptor

Results for "

NR2B

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Adrenergic Receptor (2) Akt (3) Apoptosis (1) Bacterial (1) Calcium Channel (2) CaMK (1) Cholecystokinin Receptor (3) Ephrin Receptor (3) Glutathione S-transferase (1) HIF/HIF Prolyl-Hydroxylase (3) HIV (1) iGluR (39) Influenza Virus (2) Interleukin Related (3) NO Synthase (4) P-glycoprotein (1) p38 MAPK (1) Potassium Channel (5) Reactive Oxygen Species (ROS) (1) Sigma Receptor (1) VEGFR (3)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (40)

By Targets:

17β-HSD (1)

Adrenergic Receptor (2)

Akt (3)

Apoptosis (1)

Bacterial (1)

Calcium Channel (2)

CaMK (1)

Cholecystokinin Receptor (3)

Ephrin Receptor (3)

Glutathione S-transferase (1)

HIF/HIF Prolyl-Hydroxylase (3)

HIV (1)

iGluR (39)

Influenza Virus (2)

Interleukin Related (3)

NO Synthase (4)

P-glycoprotein (1)

p38 MAPK (1)

Potassium Channel (5)

Reactive Oxygen Species (ROS) (1)

Sigma Receptor (1)

VEGFR (3)

By Research Areas:

Cancer (4)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (1)

Metabolic Disease (1)

Neurological Disease (40)

Inhibitors & Agonists

Peptides

Natural
Products

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107706

Co 101244 hydrochloride PD 174494 hydrochloride	iGluR	Neurological Disease
Co 101244 (PD 174494) hydrochloride is a NR2B-containing NMDA receptor antagonist .

HY-121100

BZAD-01	iGluR	Neurological Disease
BZAD-01 is a potent, selective and orally active inhibitor of *NMDA NR2B* subunit, with a K_i** of 72 nM. BZAD-01 can improve postural asymmetry as well as Apomorphine-induced rotation .

HY-136299

Sepimostat 2 Publications Verification FUT-187 free base	iGluR	Neurological Disease
Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat inhibits the Ifenprodil binding with a K_i value of 27.7?μM .

HY-126123

NR2B-selective NMDA receptor antagonist 1	iGluR Potassium Channel	Neurological Disease
NR2B-selective NMDA receptor antagonist 1 (compound 29) is a potent antagonist of NR1/NR2B receptors, with IC₅₀s of 0.05 μM, 0.73 μM, 2.4 μM to NR1/NR2B NMDA receptor, hERG, α1-AdR, respectivity. NR2B-selective NMDA receptor antagonist 1 exhibites efficient permeability across the blood–brain barrier .

HY-P5947

*Tat-HA-NR2B9c*	HIV	Neurological Disease
Tat-HA-NR2B9 contains a fragment of the cellmembrane transduction domain of HIV-1 Tat, a influenza virus hemagglutinin (HA) epitope-tag, and the C-terminal 9 amino acids of NR2B (NR2B9c). Tat-HA-NR2B9 reduces infarct size and improves neurological functions in ischemia-induced cerebral injury in the rats

HY-177127

Satoprodil	iGluR	Neurological Disease
Satoprodil (example 2) is a potent N-methyl-D-aspartate (NMDA) receptor negative allosteric modulator with an IC₅₀ value of 123 nM for NR2B ^[2].

HY-107698

PMPA (NMDA antagonist)	iGluR	Neurological Disease
PMPA (NMDA antagonist) is an NMDA receptor antagonist with K_i values of 0.84, 2.74, 3.53 and 4.16 μM for *NR2A, NR2B, NR2C* and *NR2D*, respectively .

HY-145585

Onfasprodil MIJ-821	iGluR	Neurological Disease
Onfasprodil is negative allosteric modulator of *NR2B*. Onfasprodil in combination with GABA receptor regulator has the potential for the research of Alzheimer's disease (extracted from patent CN111481543A) .

HY-136299A

Sepimostat dimethanesulfonate FUT-187	iGluR	Neurological Disease
Sepimostat dimethanesulfonate (FUT-187) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat dimethanesulfonate inhibits the Ifenprodil binding with a K_i value of 27.7 µM .

HY-136659

Ro 04-5595	iGluR	Others
Ro 04-5595 is a selective antagonist with specific activity against the NR2B subunit of the NMDA receptor. Ro 04-5595 exhibits favorable pharmacokinetic properties in in vitro and in vivo studies, with rapid uptake and clearance. Ro 04-5595 exhibits strong binding in NR2B receptor-enriched regions and low binding in the cerebellum. Ro 04-5595 is able to effectively inhibit specific binding, showing high affinity for the NR2B receptor and a clear ranking of binding affinity with a variety of other compounds .

HY-137049

Co 101244 PD 174494	iGluR	Others
Co-101244 (PD 174494) is an NMDA receptor blocker that specifically targets the NR2B subunit.

HY-12962

NMDA-IN-1	iGluR	Neurological Disease
NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor.

HY-111500A

NMDAR antagonist 1	iGluR	Neurological Disease
NMDAR antagonist 1 is a potent and orally bioavailable NR2B-selective NMDAR antagonist .

HY-136299R

Sepimostat (Standard)	iGluR	Neurological Disease
Sepimostat (Standard) is the analytical standard of Sepimostat. This product is intended for research and analytical applications. Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat inhibits the Ifenprodil binding with a Ki value of 27.7 μM .

HY-P0117

*Tat-NR2B9c* 5+ Cited Publications Tat-NR2Bct; NA-1	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy ^[2] .

HY-P0117A

*Tat-NR2B9c TFA* 5+ Cited Publications Tat-NR2Bct TFA; NA-1 TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-107716

Ro 8-4304 hydrochloride	iGluR	Neurological Disease
Ro 8-4304 hydrochloride is a potent NMDA receptor antagonist. Ro 8-4304 hydrochloride is a NR2B selective, non-competitive, voltage-independent antagonist .

HY-12962A

NMDA-IN-1 dihydrochloride	iGluR	Neurological Disease
NMDA-IN-1 dihydrochloride is a selective NMDA NR2B antagonist with a Ki of 0.85 nM; NR2B Ca₂₊ influx IC₅₀ is 9.7 nM. NMDA-IN-1 dihydrochloride inhibits Glu/Gly stimulated Ca₂₊ flux in Ltk- cells expressing the hNR1a/NR2B with a IC₅₀ of 9.7 nM. NMDA-IN-1 dihydrochloride has no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor. NMDA-IN-1 dihydrochloride shows excellent activity in the mechanical hyperalgesia assay in rats. NMDA-IN-1 dihydrochloride can be used for the studies of stroke, parkinson, and neuropathic pain .

HY-111500

(Rac)-NMDAR antagonist 1	iGluR	Neurological Disease
(Rac)-NMDAR antagonist 1 is the racemate of NMDAR antagonist 1. NMDAR antagonist 1 is a potent and orally bioavailable NR2B-selective NMDAR antagonist .

HY-14777

Radiprodil RGH-896	iGluR	Neurological Disease
Radiprodil (RGH-896) is an orally active and selective NMDA NR2B antagonist. A potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions .

HY-170410

EMD-95885	iGluR	Neurological Disease
EMD-95885 is a selective NR2B-containing NMDA receptors antagonist with an IC₅₀ of 3.9 nM. EMD-95885 does not interact with other sites on the NMDA receptor .

HY-136459

NMDA receptor antagonist 2	iGluR	Neurological Disease
NMDA receptor antagonist 2 is a potent and orally active NR2B subtype-selective NMDA antagonist with an IC₅₀ and a K_i of 1.0 nM and 0.88 nM, respectively. NMDA receptor antagonist 2 is used for the study of neuropathic pain and Parkinson’s disease .

HY-12881

Eliprodil SL-820715	iGluR	Neurological Disease
Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM).

HY-106408A

Nelonemdaz potassium Salfaprodil; Neu2000 potassium	iGluR	Neurological Disease
Nelonemdaz (Salfaprodil) potassium is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz potassium is also a free radical scavenger. Nelonemdaz potassium has excellent neuroprotection against NMDA- and free radical-induced cell death ^[2].

HY-116142

CP-283097	iGluR	Neurological Disease
CP-283097 is a conformationally restricted and *NR2B* subtype-selective NMDA antagonist. CP-283097 efficiently competitively inhibits the binding of [³H]CP-101,606 to the rat meninges, with an IC₅₀ value of 18 nM. CP-283097 exhibits nearly complete inhibition of the current mediated by the NR2B receptor (IC₅₀ = 206 nM), while the inhibitory effect on the NR2A or NR2C receptors is very weak. CP-283097 demonstrates excellent central nervous system permeability and in vivo efficacy in animal models. CP-283097 can be used for neurological diseases related to excessive activation of NMDA receptors .

HY-14777R

Radiprodil (Standard)	iGluR	Neurological Disease
Radiprodil (Standard) is the analytical standard of Radiprodil. This product is intended for research and analytical applications. Radiprodil (RGH-896) is an orally active and selective NMDA NR2B antagonist. A potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions .

HY-106408

Nelonemdaz Salfaprodil free base; Neu2000	iGluR	Neurological Disease
Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA- and free radical-induced cell death ^[2].

HY-13993B

Ro 25-6981 hydrochloride	iGluR	Neurological Disease
Ro 25-6981 hydrochloride is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 hydrochloride shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 hydrochloride has the potential for the research of parkinson's disease (PD) ^[2] .

HY-13993

Ro 25-6981 5+ Cited Publications	iGluR	Neurological Disease
Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD) ^[2] .

HY-13993A

Ro 25-6981 Maleate 5+ Cited Publications	iGluR	Neurological Disease
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD) ^[2] .

HY-12882AR

Ifenprodil tartrate (Standard) NP-120 tartrate (Standard); RC-61-91 tartrate (Standard)	iGluR Potassium Channel	Neurological Disease
Ifenprodil (tartrate) (Standard) is the analytical standard of Ifenprodil (tartrate). This product is intended for research and analytical applications. Ifenprodil tartrate is a typical noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has the potential to be a cerebral vasodilator ^[2].

HY-161211

HSD17B13-IN-7	17β-HSD iGluR	Metabolic Disease
HSD17B13-IN-7 (compound 1), a fluorophenol-containing compound, is a potent HSD17B13 inhibitor with IC₅₀s of 0.18 μM and 0.25 μM β-estradiol and Leukotriene B4 as substrates, respectively. HSD17B13-IN-7 is a potent N-methyl-D-aspartate (NMDA) NR2B receptor antagonist. HSD17B13-IN-7 has the potential for non-alcoholic fatty liver disease research .

HY-P2307

Tat-NR2Baa	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 ^[2].

HY-P2307A

Tat-NR2Baa TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

HY-117467

BMT-108908	iGluR	Neurological Disease
BMT-108908 is a negative allosteric modulator with selective activity on the NR2B subtype of the NMDA receptor. BMT-108908 has been shown to damage cognition in research, affecting cognitive functions in multiple areas. BMT-108908 failed to show a significant impact on the γ wave power of the EEG in the experiment, but it had a significant inhibitory and enhancement effect on the β wave and δ wave power .

HY-107708

threo-Ifenprodil hemitartrate	iGluR Sigma Receptor Potassium Channel	Neurological Disease
threo Ifenprodil hemitartrate is a σ receptor agonist, with K_is of 59.1 and 2 nM for σ1 and σ2 receptors, respectively. threo Ifenprodil hemitartrate is also a *NR2B* subunit-selective NMDA receptor antagonist (IC₅₀=0.22 μM). threo Ifenprodil hemitartrate is a hERG potassium channel inhibitor, with an IC ₅₀ of 88 nM, showing antiarrhythmic activity ^[2] .

HY-105353

CEB-1604	iGluR	Neurological Disease
CEB-1604 is an NMDA receptor antagonist. CEB-1604 inhibits NMDA-induced currents in oocytes transfected with NMDA receptor isoforms (NR1/NR2A, NR1/NR2B, NR1/NR2C, NR1/NR2D) with IC₅₀ values ranging from 5 to 12 μM. CEB-1604 abolishes NMDA-dependent epileptiform discharges in rat cortical wedge preparations and reduces the depolarizing effects of NMDA. CEB-1604 can be used in the research field of neurological damage diseases .

HY-17617

Nastorazepide Z-360	Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt	Neurological Disease Cancer
Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and *gastrin/CCK-2* receptor antagonist. Nastorazepide inhibits the specific binding of [ ³H]CCK-8 to the human CCK-2 receptor with a K_i value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and *NR2B* phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain ^[2] .

HY-14575

Nastorazepide hemicalcium Z-360 hemicalcium	Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt	Neurological Disease Cancer
Nastorazepide (Z-360) hemicalcium is an orally active 1,5-benzodiazepine derivative and *gastrin/CCK-2* receptor antagonist. Nastorazepide hemicalcium inhibits the specific binding of [ ³H]CCK-8 to the human CCK-2 receptor with a K_i value of 0.47 nM. Nastorazepide hemicalcium inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and *NR2B* phosphorylation. Nastorazepide hemicalcium has antitumor activity against pancreatic cancer. Nastorazepide hemicalcium inhibits colorectal cancer liver metastasis and relieves pain ^[2] .

HY-17617R

Nastorazepide (Standard)	Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt	Neurological Disease Cancer
Nastorazepide (Standard) is the analytical standard of Nastorazepide. This product is intended for research and analytical applications. Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain ^[2] .

HY-N1916

Coniferyl ferulate	Glutathione S-transferase P-glycoprotein Apoptosis iGluR CaMK p38 MAPK Reactive Oxygen Species (ROS) Bacterial	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Coniferyl ferulate is an orally active phenolic acid compound. Coniferyl ferulate is a potent inhibitor of glutathione S-transferase (GST) (IC₅₀ = 0.3 μM), which downregulates P-gp expression, induces apoptosis in B-MD-C1 (ADR+/+) cells, and reverses multidrug resistance. Coniferyl ferulate blocks the *NMDAR/NR2B-CaMKII-MAPKs* signaling pathway, inhibits ROS production and mitochondrial apoptosis, while reshapes the intestinal microbiota and microbial metabolism, ameliorates colonic inflammation and alleviates depressive symptoms in mice. Coniferyl ferulate can alleviate the toxicity of xylene to hematopoietic stem and progenitor cells by targeting *Mgst2. Coniferyl ferulate exhibits antibacterial activity against the Gram-positive Bacillus subtilis* and Staphylococcus aureus ^[2] .

HY-12882

Ifenprodil Maximum Cited Publications 10 Publications Verification NP-120; RC-61-91	iGluR Adrenergic Receptor Potassium Channel Calcium Channel Influenza Virus	Infection Neurological Disease
Ifenprodil (NP-120), a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil exerts high affinity at NR1A/NR2B receptors (IC₅₀=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC₅₀=146 μM) . Ifenprodil is an α1 adrenergic receptor antagonist. Ifenprodil inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil has reliable inhibitory effects against A/H1N1 strains (EC₅₀ of 6.6 µM). Ifenprodil has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease ^[2] .

HY-12882A

Ifenprodil tartrate Maximum Cited Publications 10 Publications Verification NP-120 tartrate; RC-61-91 tartrate	iGluR Adrenergic Receptor Potassium Channel Calcium Channel Influenza Virus	Infection Neurological Disease
Ifenprodil (NP-120) tartrate, a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC₅₀=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC₅₀=146 μM) . Ifenprodil tartrate is an α1 adrenergic receptor antagonist. Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has reliable inhibitory effects against A/H1N1 strains (EC₅₀ of 6.6 µM). Ifenprodil tartrate has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil tartrate can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease ^[2] .

Cat. No.	Product Name	Target	Research Area

HY-P0117

*Tat-NR2B9c* 5+ Cited Publications Tat-NR2Bct; NA-1	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy ^[2] .

HY-P0117A

*Tat-NR2B9c TFA* 5+ Cited Publications Tat-NR2Bct TFA; NA-1 TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-P2307

Tat-NR2Baa	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 ^[2].

HY-P5947

*Tat-HA-NR2B9c*	HIV	Neurological Disease
Tat-HA-NR2B9 contains a fragment of the cellmembrane transduction domain of HIV-1 Tat, a influenza virus hemagglutinin (HA) epitope-tag, and the C-terminal 9 amino acids of NR2B (NR2B9c). Tat-HA-NR2B9 reduces infarct size and improves neurological functions in ischemia-induced cerebral injury in the rats

HY-P2307A

Tat-NR2Baa TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1916

Coniferyl ferulate	Classification of Application Fields Simple Phenylpropanols Source classification Phenols Polyphenols Dicerothamnus rhinocerotis Phenylpropanoids Umbelliferae Plants Disease Research Fields Cancer	Glutathione S-transferase P-glycoprotein Apoptosis iGluR CaMK p38 MAPK Reactive Oxygen Species (ROS) Bacterial
Coniferyl ferulate is an orally active phenolic acid compound. Coniferyl ferulate is a potent inhibitor of glutathione S-transferase (GST) (IC₅₀ = 0.3 μM), which downregulates P-gp expression, induces apoptosis in B-MD-C1 (ADR+/+) cells, and reverses multidrug resistance. Coniferyl ferulate blocks the *NMDAR/NR2B-CaMKII-MAPKs* signaling pathway, inhibits ROS production and mitochondrial apoptosis, while reshapes the intestinal microbiota and microbial metabolism, ameliorates colonic inflammation and alleviates depressive symptoms in mice. Coniferyl ferulate can alleviate the toxicity of xylene to hematopoietic stem and progenitor cells by targeting *Mgst2. Coniferyl ferulate exhibits antibacterial activity against the Gram-positive Bacillus subtilis* and Staphylococcus aureus ^[2] .

HY-12882A

Ifenprodil tartrate 5+ Cited Publications NP-120 tartrate; RC-61-91 tartrate	Alkaloids Piperidine Alkaloids Neurological Disease Classification of Application Fields Crassulaceae Source classification Sedum sarmentosum Bunge Plants Disease Research Fields	iGluR Adrenergic Receptor Potassium Channel Calcium Channel Influenza Virus
Ifenprodil (NP-120) tartrate, a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC₅₀=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC₅₀=146 μM) . Ifenprodil tartrate is an α1 adrenergic receptor antagonist. Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has reliable inhibitory effects against A/H1N1 strains (EC₅₀ of 6.6 µM). Ifenprodil tartrate has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil tartrate can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease ^[2] .

HY-12882AR

Ifenprodil tartrate (Standard) NP-120 tartrate (Standard); RC-61-91 tartrate (Standard)	Alkaloids Piperidine Alkaloids Crassulaceae Source classification Sedum sarmentosum Bunge Plants	iGluR Potassium Channel
Ifenprodil (tartrate) (Standard) is the analytical standard of Ifenprodil (tartrate). This product is intended for research and analytical applications. Ifenprodil tartrate is a typical noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has the potential to be a cerebral vasodilator ^[2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82068

	CoREST Antibody (YA1813) COREST; NR2B2; RCOR; Rcor1; Rxrb	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	CoREST Antibody (YA1813) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CoREST.

HY-P87060

	Retinoid X Receptor beta/RXRB Antibody (YA6753) DAUD I6 antibody; DAUDI6 antibody; H 2RIIBP antibody; H2RIIBP antibody; MGC1831 antibody; MHC class I promoter binding protein antibody; NR2B2 antibody; Nuclear receptor subfamily 2 group B member 2 antibody; RCoR 1 antibody; RCoR1 antibody; DAUD I6 antibody; DAUDI6 antibody; H 2RIIBP antibody; H2RIIBP antibody; MGC1831 antibody; MHC class I promoter binding protein antibody; NR2B2 antibody; Nuclear receptor subfamily 2 group B member 2 antibody; RCoR 1 antibody; RCoR1 antibody; Retinoic acid receptor RXR beta antibody; Retinoic acid receptor RXR-beta antibody; Retinoid X receptor beta antibody; RXR beta antibody; Rxrb antibody; RXRB_HUMAN antibody; RXRbeta antibody;	WB, ICC/IF, IHC-P	Human, Mouse, Rat
	Retinoid X Receptor beta/RXRB Antibody (YA6753) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Retinoid X Receptor beta/RXRB.

HY-P84531

	GRIN2B Antibody (YA4228) MRD6; NR2B; hNR3; EIEE27; GluN2B; NMDAR2B	ICC/IF, FC, ELISA	Human
	GRIN2B Antibody (YA4228) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GRIN2B.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks